Combination inhalers containing inhaled corticosteroids and long-acting β2-agonists: Improved clinical efficacy and dosing options in patients with asthma

Journal of Asthma

Volumn 42, Issue 9, 2005, Pages 715-724

  Ankerst, Jaro ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Budesonide formoterol; Inhaled corticosteroid; Long acting 2 agonist; Salmeterol fluticasone; Seretide Advair ; Symbicort

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE; BUDESONIDE PLUS FORMOTEROL; CORTICOSTEROID; FLUTICASONE; FLUTICASONE PROPIONATE; LONG ACTING DRUG; SALMETEROL;

ASTHMA; CLINICAL TRIAL; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; EXPERIENCE; HUMAN; INHALER; RECOGNITION; REVIEW; SIDE EFFECT;

ADMINISTRATION, INHALATION; ADRENAL CORTEX HORMONES; ADRENERGIC BETA-AGONISTS; ADULT; ALBUTEROL; ANDROSTADIENES; ANTI-ASTHMATIC AGENTS; ASTHMA; BUDESONIDE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG COMBINATIONS; ETHANOLAMINES; HUMANS; NEBULIZERS AND VAPORIZERS; TREATMENT OUTCOME;

EID: 28744445466     PISSN: 02770903     EISSN: 15324303     Source Type: Journal    
DOI: 10.1080/02770900500305748     Document Type: Review

References (63)

1. Global Initiative for Asthma (GINA). Global Strategy for Asthma Management and Prevention. National Institutes of Health: National Heart, Lung, and Blood Institute. Bethesda, MD: National Institutes of Health, 2002. (Publication no. NIH-NHLI 02-3569).
2. British Thoracic Society. British guidelines on the management of asthma. Thorax 2003; 58(suppl 1):1-94.
3. Barnes PJ, Pedersen S, Busse WW. Efficacy and safety of inhaled corticosteroids. New developments. Am J Respir Crit Care Med 1998; 157(3 Pt 2):S1-S53.
4. Ebeling PR, Erbas B, Hopper JL, Wark JD, Rubinfeld AR. Bone mineral density and bone turnover in asthmatics treated with long-term inhaled or oral glucocorticoids. J Bone Miner Res 1998; 13:1283-1289.
5. Lipworth BJ, Jackson CM. Safety of inhaled and intranasal corticosteroids. Lessons for the new millennium. Drug Saf 2000; 23:11-33.
6. Greening AP, Ind PW, Northfield M, Shaw G. Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid. Lancet 1994; 344:219-224.
7. Woolcock A, Lundback B, Ringdal N, Jacques LA. Comparison of addition of salmeterol to inhaled steroids with doubling the dose of inhaled steroids. Am J Respir Crit Care Med 1996; 153:1481-1488.
8. Pauwels RA, Lofdahl C-G, Postma DS, Tattersfield AE, O'Byrne P, Barnes PJ, Ullman A. Effect of inhaled formoterol and budesonide on exacerbations of asthma. N Engl J Med 1997; 337:1405-1411.
9. Jenkins C, Woolcock AJ, Saarelainen P, Lundbäck B, James MH. Salmeterol/fluticasone propionate combination therapy 50/250 μg twice daily is more effective than budesonide 800 μg twice daily in treating moderate to severe asthma. Respir Med 2000; 94:715-723.
10. Lipworth BJ. Airway subsensitivity with long-acting beta 2-agonists. Is there cause for concern? Drug Saf 1997; 16:295-308.
11. McIvor RA, Pizzichini E, Turner MO, Hussack P, Hargreave FE, Sears MR. Potential masking of effects of salmeterol on airway inflammation in asthma. Am J Respir Crit Care Med 1998; 158:924-930.
12. Kips JC, O'Connor BJ, Inman MD, Svensson K, Pauwels RA, O'Byrne PM. A long-term study of the anti-inflammatory effect of low-dose budesonide plus formoterol versus high-dose budesonide in asthma. Am J Respir Crit Care Med 2000; 161:996-1001.
13. 2-agonists and corticosteroids. Eur Respir J 2002; 19:182-191.
14. Horn CR, Clark TJH, Cochrane GM. Compliance with inhaled therapy and morbidity from asthma. Respir Med 1990; 84:67-70.
15. Eisner MD, Lieu TA, Capra AM, Mendoza GR, Selby JV, Blanc PD. Beta agonists, inhaled steroids, and the risk of intensive care unit admission for asthma. Eur Respir J 2001; 17:233-240.
16. van der Palen J, Klein JJ, van Herwaarden CLA, Zielhuis GA, Seydel ER. Multiple inhalers confuse asthma patients. Eur Respir J 1999; 14:1034-1037.
17. Cochrane GM. Compliance in asthma. Eur Respir Rev 1998; 8:348-350.
18. Campbell LM. Once-daily inhaled corticosteroids in mild to moderate asthma. Improving acceptance of treatment. Drugs 1999; 58(suppl 4):25-33.
19. Buhl R. Budesonide/formoterol for the treatment of asthma. Expert Opin Pharmacother 2003; 4:1393-1406.
20. Markham A, Jarvis B. Inhaled salmeterol/fluticasone propionate combination: a review of its use in persistent asthma. Drugs 2000; 60:1207-1233.
21. Miller-Larsson A, Mattsson H, Hjertberg E, Dahlbäck M, Tunek A, Brattsand R. Reversible fatty acid conjugation of budesonide. Novel mechanism for prolonged retention of topically applied steroid in airway tissue. Drug Metab Dispos 1998; 26:623-630.
22. Miller-Larsson A, Jansson P, Runström A, Brattsand R. Prolonged airway activity and improved selectivity of budesonide possibly due to esterification. Am J Respir Crit Care Med 2000; 162:1455-1461.
23. Thorsson L, Thunnisen FBJM, Korn S, Carlshof A, Edsbäcker S, Wouters EFM. Formation of fatty acid conjugates of budesonide in human lung tissue in vivo [abstr]. Am J Respir Crit Care Med 1998; 157(suppl 3):A404.
24. Edsbäcker S, Szefler SJ. Glucocorticoid pharmacokinetics: principles and clinical applications. In: Schleimer RP, Busse WW, O'Byrne PM, eds. Inhaled Glucocorticoids in Asthma: Mechanisms and Clinical Actions. New York: Marcel Dekker, 1997:381-445.
25. Lipworth BJ. Systemic adverse effects of inhaled corticosteroid therapy: a systematic review and meta-analysis. Arch Intern Med 1999; 159:941-955.
26. Palmqvist M, Arvidsson P, Beckman P, Peterson S, Lötvall J. Onset of bronchodilation of budesonide/formoterol vs. salmeterol/fluticasone in single inhalers. Pulm Pharmacol Ther 2001; 14:29-34.
27. Balanag VM, Yunus F, Yang P-C, Jorup C. Budesonide/formoterol in a single inhaler is as effective and well tolerated as salbutamol in relieving acute asthma in adults and adolescents [abstr P2836]. Eur Respir J 2003; 22(suppl 45):445s.
28. van der Woude HJ, Boorsma M, Bergqvist PB, Winter TH, Aalbers R. Budesonide/formoterol in a single inhaler rapidly relieves methacholine-induced moderate-to-severe bronchoconstriction. Pulm Pharmacol Ther 2004; 17:89-95.
29. Aziz I, Wilson AM, Lipworth BJ. Effects of once-daily formoterol and budesonide given alone or in combination on surrogate inflammatory markers in asthmatic adults. Chest 2000; 118:1049-1058.
30. 2-agonists, improve the perception of bronchoconstriction in asthma. Am J Respir Crit Care Med 2001; 164:764-769.
31. Barnes PJ. Poorly perceived asthma. Thorax 1992; 47:408-409.
32. Kikuchi Y, Okabe S, Tamura G, Hida W, Homma M, Shirato K, Takishima T. Chemosensitivity and perception of dyspnea in patients with a history of near-fatal asthma. N Engl J Med 1994; 330:1329-1334.
33. Busse WW, Chervinsky P, Condemi J, Lumry WR, Petty TL, Rennard S, Townley RG. Budesonide delivered by Turbuhaler is effective in a dose-dependent fashion when used in the treatment of adult patients with chronic asthma. J Allergy Clin Immunol 1998; 101:457-463.
34. Palmqvist M, Ibsen T, Mellén A, Lötvall J. Comparison of the relative efficacy of formoterol and salmeterol in asthmatic patients. Am J Respir Crit Care Med 1999; 160:244-249.
35. Bateman ED, Britton M, Almeida J, Wixon C. Salmeterol/fluticasone combination inhaler. A new, effective and well-tolerated treatment for asthma. Clin Drug Investig 1998; 16:193-201.
36. Kavuru M, Melamed J, Gross G, Laforce C, House K, Prillaman B, Baitinger L, Woodring A, Shah T. Salmeterol and fluticasone propionate combined in a new powder inhalation device for the treatment of asthma: a randomized, double-blind, placebo-controlled trial. J Allergy Clin Immunol 2000; 105:1108-1116.
37. Shapiro G, Lumry W, Wolfe J, Given J, White MV, Woodring A, Baitinger L, House K, Prillaman B, Shah T. Combined salmeterol 50 μg and fluticasone propionate 250 μg in the Diskus device for the treatment of asthma. Am J Respir Crit Care Med 2000; 161:527-534.
38. Johansson G, McIvor RA, Purello D'Ambrosio F, Gratziou C, James MH. Comparison of salmeterol/fluticasone propionate combination with budesonide in patients with mild-to-moderate asthma. Clin Drug Investig 2001; 21:633-642.
39. Busse W, Koenig SM, Oppenheimer J, Sahn SA, Yancey SW, Reilly D, Edwards LD, Dorinsky PM. Steroid-sparing effects of fluticasone propionate 100 μg and salmeterol 50 μg administered b.i.d. in a single product in patients previously controlled with fluticasone propionate 250 μg administered b.i.d.. J Allergy Clin Immunol 2003; 111:57-65.
40. Jenkins C, Woolcock AJ, Saarelainen P, Lundbäck B, James MH. Salmeterol/fluticasone propionate combination therapy 50/250 μg b.i.d. is more effective than budesonide 800 μg b.i.d. in treating moderate to severe asthma. Respir Med 2000; 94:715-723.
41. Chapman KR, Ringdal N, Backer V, Palmqvist M, Saarelainen S, Briggs M. Salmeterol and fluticasone propionate (50/250 microg) administered via combination Diskus inhaler: as effective as when given via separate Diskus inhalers. Can Respir J 1999; 6:45-51.
42. Aubier M, Pieters W, Schlosser N, Steinmetz K-O. Salmeterol/ fluticasone propionate (50/500 μg) in combination in a Diskus inhaler (Seretide) is effective and safe in the treatment of steroid-dependent asthma. Respir Med 1999; 93:876-884.
43. Van den Berg NJ, Ossip MS, Hederos CA, Anttila H, Ribeiro BL, Davies PI. Salmeterol/fluticasone propionate (50/100 μg) in combination in a Diskus™ inhaler (Seretide™) is effective and safe in children with asthma. Pediatr Pulmonol 2000; 30:97-105.
44. Nelson HS, Chapman KR, Pyke SD, Johnson M, Pritchard JN. Enhanced synergy between fluticasone propionate and salmeterol inhaled from a single inhaler versus separate inhalers. J Allergy Clin Immunol 2003; 112:29-36.
45. Bateman ED, Boushey HA, Bousquet J, Busse WW, Clark TJ, Pauwels RA, Pedersen SE, GOAL Investigators Group. Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL Study. Am J Respir Crit Care Med 2004; 170:836-844.
46. Zetterström O, Buhl R, Mellem H, Perpiña M, Hedman J, O'Neill S, Ekstrom T. Improved asthma control with budesonide/formoterol in a single inhaler, compared with budesonide alone. Eur Respir J 2001; 18:262-268.
47. Rosenhall L, Heinig JH, Lindqvist A, Leegaard J, Stahl E, Bergqvist PB. Budesonide/formoterol (Symbicort®) is well tolerated and effective in patients with moderate persistent asthma. Int J Clin Pract 2002; 56:427-433.
48. Rosenhall L, Elvstrand A, Tilling B, Vinge I, Jemsby P, Stahl E, Jerre F, Bergqvist PB. One-year safety and efficacy of budesonide/formoterol in a single inhaler (Symbicort Turbuhaler) for the treatment of asthma. Respir Med 2003; 97:702-708.
49. Lalloo UJ, Malolepszy J, Kozma D, Krofta K, Ankerst J, Johansen B, Thomson NC. Budesonide and formoterol in a single inhaler improves asthma control compared with increasing the dose of corticosteroid in adults with mild-to-moderate asthma. Chest 2003; 123:1480-1487.
50. Bateman ED, Bantje TA, Joao Gomes M, Toumbis M, Huber R, Naya I, Eliraz A. Combination therapy with single inhaler budesonide/formoterol compared with high dose of fluticasone propionate alone in patients with moderate persistent asthma. Am J Respir Med 2003; 2:275-281.
51. Palmqvist M, Persson G, Lazer L, Rosenborg J, Larsson P, Lötvall J. Inhaled dry powder formoterol and salmeterol in asthmatic patients: onset of action, duration of effect and potency. Eur Respir J 1997; 10:2484-2489.
52. Buhl R, Creemers JPHM, Vondra V, Martelli NA, Naya IP, Ekstrom T. Once-daily budesonide/formoterol in a single inhaler in moderate persistent asthma. Respir Med 2003; 97:323-330.
53. Chisholm SL, Dekker FW, Knuistingh Neven A, Petri H. Once-daily budesonide in mild asthma. Respir Med 1998; 92:421-425.
54. Herjavecz I, Blomqvist P, Serrano A. Efficacy of once- and twice-daily administration of budesonide via Turbuhaler® as initial therapy in patients with mild persistent asthma. Respir Med 1999; 93:230-235.
55. McFadden ER, Casale TB, Edwards TB, Kemp JP, Metzger WJ, Nelson HS, Storms WW, Neidl MJ. Administration of budesonide once daily by means of turbuhaler to subjects with stable asthma. J Allergy Clin Immunol 1999; 104:46-52.
56. Foresi A, Morelli MC, Catena E, on behalf of the Italian Study Group. Low-dose budesonide with the addition of an increased dose during exacerbations is effective in long-term asthma control. Chest 2000; 117:440-446.
57. Ställberg B, Olsson P, Jörgensen LA, Lindarck N, Ekström T. Budesonide/formoterol adjustable maintenance dosing reduces asthma exacerbations versus fixed dosing. Int J Clin Pract 2003; 57:656-661.
58. Leuppi JD, Salzberg M, Meyer L, Bucher SE, Nief M, Brutsche MH, Tamm M. An individualized, adjustable maintenance regimen of budesonide/formoterol provides effective asthma symptom control at a lower overall dose than fixed dosing. Swiss Med Wkly 2003; 133:302-309.
59. FitzGerald JM, Sears MR, Boulet L-P, Becker AB, McIvor AR, Ernst P, Smiljanic-Georgijev NM, Lee JS, Canadian Investigators. Adjustable maintenance dosing with budesonide/formoterol reduces asthma exacerbations compared with traditional fixed dosing: a five-month multicentre Canadian study. Can Respir J 2003; 10:427-434.
60. Aalbers R, Backer V, Kava TT, Omenaas ER, Sandström T, Jorup C, Welte T. Adjustable dosing with budesonide/formoterol compared with fixed dosing salmeterol/fluticasone in moderate to severe asthma. Curr Med Res Opin 2004; 20:225-240.
61. O'Byrne PM, Bisgaard H, Godard PP, Pistolesi M, Palmqvist M, Zhu Y, Ekstrom T, Bateman ED. Budesonide/formoterol combination therapy as both maintenance and reliever medication in asthma. Am J Respir Crit Care Med 2005; 171:129-136.
62. Scicchitano R, Aalbers R, Ukena D, Manjra AI, Fouquert L, Centanni S, Boulet LP, Naya IP, Hultquist C. Efficacy and safety of budesonide/formoterol single inhaler therapy versus a higher dose of budesonide in moderate to severe asthma. Curr Med Res Opin 2004; 20:1403-1418.
63. Rabe KF, Pizzichini E, Ställberg B, Romero S, Balanzat A, Soerensen T, Atienza T. Single inhaler therapy with budesonide/formoterol provides superior asthma control compared with fixed dosing with budesonide plus terbutaline as needed [abstr 360]. J Allergy Clin Immunol 2004; 113(suppl 2):S116.